{
    "clinical_study": {
        "@rank": "23194", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "AZD8683 iv"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "AZD8683 oral"
            }, 
            {
                "arm_group_label": "3", 
                "arm_group_type": "Experimental", 
                "description": "AZD8683 inhalation New Dry Powder Inhaler"
            }, 
            {
                "arm_group_label": "4", 
                "arm_group_type": "Experimental", 
                "description": "AZD8683 inhalation Turbuhaler\u2122"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to look at drug levels of AZD8683 in blood when the drug is\n      administered in different ways - orally, intravenously or inhaled (with two different\n      devices), to healthy subjects"
        }, 
        "brief_title": "A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in\n      Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 when\n      Administered Inhaled via a New Dry Powder Inhaler and via Turbuhaler\u2122"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or women of non-childbearing potential aged 18-45 years inclusive with\n             suitable veins for cannulation or repeated vein puncture\n\n          -  Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive) and weight between\n             50 and 100 kg (inclusive)\n\n          -  Be able to inhale from the inhaler devices used in the study.\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant disease or disorder\n\n          -  Current smokers\n\n          -  Any clinically relevant abnormal findings in physical examination or laboratory\n             values."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666613", 
            "org_study_id": "D1883C00008", 
            "secondary_id": "EudraCT number 2012-002901-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "1", 
                "description": "Solution for injection, administered as intravenous infusion Total dose of 100\u00b5g AZD8683", 
                "intervention_name": "AZD8683", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "Solution to be administered orally Total dose of 950 \u00b5g AZD8683", 
                "intervention_name": "AZD8683", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3", 
                "description": "Dry powder  inhaled via New Dry Powder Inhaler, 540 \u00b5g delivered dose AZD8683", 
                "intervention_name": "AZD8683", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4", 
                "description": "Dry powder  inhaled via Turbuhaler\u2122, 600 \u00b5g delivered dose AZD8683", 
                "intervention_name": "AZD8683", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase I, Healthy volunteers, pharmacokinetics", 
            "Bioavailability", 
            "AUC"
        ], 
        "lastchanged_date": "December 18, 2012", 
        "number_of_arms": "4", 
        "official_title": "A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 When Administered Inhaled Via a New Dry Powder Inhaler and Via Turbuhaler\u2122", 
        "overall_official": {
            "affiliation": "AstraZeneca R&D, Molndal Sweden", 
            "last_name": "Carin Jorup, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absolute pulmonary bioavailability of AZD8683 delivered by the new dry powder inhaler in terms of:  Fpulmonary", 
            "safety_issue": "No", 
            "time_frame": "Blood samples taken pre-dose and at 5, 15  and 30 minutes and 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Absolute pulmonary bioavailability of AZD8683 delivered by the Turbuhaler\u2122 in terms of:  Fpulmonary", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at 5, 15  and 30 minutes and 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post dose."
            }, 
            {
                "measure": "Pharmacokinetics of AZD8683 following  administration in terms of oral inhalation by Turbuhaler\u2122 and New Dry Powder Inhaler in terms of: Finhalation total, FrelAUC, Frel Cmax and Foral", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at 5, 15  and 30 minutes and 1, 2, 4, 8, 12,24, 36, 48, 72, 96, 120 and 144 hours post dose."
            }, 
            {
                "measure": "Pharmacokinetics of AZD8683 following oral administration in terms of: Fpo", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at 5, 15  and 30 minutes and 1, 2, 4, 8, 12 ,24, 36, and 48 hours post dose."
            }, 
            {
                "measure": "Pharmacokinetics of AZD8683 following oral administration  and oral inhalation by Turbuhaler\u2122 and New Dry Powder inhaler in terms of : AUC, AUC(0-t), Cmax, tmax, t\u00bd\u03bbz, MRT and MAT.", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at 5, 15  and 30 minutes and 1, 2, 4, 8, 12,24, 36, 48, 72 96, 120 and 144 hours post dose."
            }, 
            {
                "measure": "Pharmacokinetics of AZD8683 following i.v. administration in terms of: CL, Vz, and Vss", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at 5, 15, 20, 25 and 40 minutes and 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 144 hours post dose."
            }, 
            {
                "description": "No formal statistical tests will be performed.", 
                "measure": "Safety profile in terms of adverse events, ECG, heart rate, blood pressure, body temperature, physical examination, spirometry, haematology, clinical chemistry and urinalysis.", 
                "safety_issue": "Yes", 
                "time_frame": "Screening to 4 weeks after last dose."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}